Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 5/20 | 0.54 |
| ▸ | L3MBTL3 | Q96JM7 | 5/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | HTT | P42858 | 2/20 | 0.52 |
| ▸ | PARP1 | P09874 | 3/20 | 0.51 |
| ▸ | MBTD1 | Q05BQ5 | 3/20 | 0.48 |
| ▸ | NAMPT | P43490 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14889527 | 0.89 | L3MBTL3 (0.49) | L3MBTL1L3MBTL3MBTD1 | |
| SCHEMBL117191 | 0.85 | L3MBTL3 (0.52) | L3MBTL1L3MBTL3MBTD1 | |
| SCHEMBL23029471 | 0.84 | HPGD (0.55) | ALDH1A1POLB | |
| SCHEMBL118381 | 0.83 | LRRK2 (0.47) | L3MBTL1L3MBTL3KDM4EALDH1A1MBTD1 | |
| SCHEMBL118545 | 0.82 | KMT2A (0.44) | L3MBTL1L3MBTL3MBTD1 | |
| SCHEMBL15996442 | 0.80 | NAMPT (0.43) | L3MBTL1L3MBTL3KDM4EALDH1A1POLB | |
| SCHEMBL118063 | 0.80 | NAMPT (0.43) | L3MBTL1L3MBTL3KDM4EALDH1A1POLB | |
| SCHEMBL3946115 | 0.80 | L3MBTL1 (0.55) | L3MBTL1L3MBTL3KDM4EALDH1A1POLB | |
| SCHEMBL117560 | 0.79 | CCR3 (0.42) | L3MBTL1L3MBTL3MBTD1 | |
| SCHEMBL118338 | 0.79 | ENPP2 (0.52) | L3MBTL1L3MBTL3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9353082-B2 | Pharmaceutical compounds | BIAL—PORTELA & CA, S.A. (PT) | 2016-05-31 | — | — | US | disclosed |
| US-9353082-B2 | Pharmaceutical compounds | BIAL—PORTELA & CA, S.A. (PT) | 2016-05-31 | — | — | US | disclosed |
| US-9353082-B2 | Pharmaceutical compounds | BIAL—PORTELA & CA, S.A. (PT) | 2016-05-31 | — | — | US | disclosed |
| US-20120065191-A1 | PHARMACEUTICAL COMPOUNDS | BIAL - PORTELA & Cª, S.A. (PT) | 2012-03-15 | — | — | US | disclosed |
| US-20120065191-A1 | PHARMACEUTICAL COMPOUNDS | BIAL - PORTELA & Cª, S.A. (PT) | 2012-03-15 | — | — | US | disclosed |
| US-20120065191-A1 | PHARMACEUTICAL COMPOUNDS | BIAL - PORTELA & Cª, S.A. (PT) | 2012-03-15 | — | — | US | disclosed |
| EP-2382012-A2 | PHARMACEUTICAL COMPOUNDS | Bial-Portela & CA, S.A. (PT) | 2011-11-02 | — | — | EP | disclosed |
| WO-2010074588-A2 | PHARMACEUTICAL COMPOUNDS | BIAL - PORTELA & Cª, S.A. (PT) | 2010-07-01 | — | — | WO | disclosed |
| WO-2010074588-A2 | PHARMACEUTICAL COMPOUNDS | BIAL - PORTELA & Cª, S.A. (PT) | 2010-07-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120065191-A1 | PHARMACEUTICAL COMPOUNDS | FAAH, FAAH2, ASAH1 | L3MBTL1 4550/4885L3MBTL3 4647/4885KDM4E 1982/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.